Next-generation synthetic cellular controls

The problem

The advancement of next-generation cell therapies is limited by manufacturing costs and the availability of live cell standards.

The solution

Synthetic cells that can accurately mimic the properties of live cells in cell manufacturing and diagnostics applications.

Our engagement

Anterra participated in the Series A round alongside Northpond Ventures and Arch Ventures.